Monthly Archives: November 2013

Biothera’s Phase 2b Study in Non-Small Cell Lung Cancer Meets Primary Endpoint

Objective response rate for Imprime PGG® combination treatment more than double rate of the control group EAGAN, MN — November 4, 2013 — Biothera announced today top-line results from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone. Full data...

Read More